Fate Therapeutics, Inc.FATENASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank72
5Y CAGR-33.2%
Year-over-Year Change
Year-over-year operating cash flow growth rate
5Y CAGR
-33.2%/yr
Long-term compound
Percentile
P72
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 4.35% |
| Q3 2025 | 0.87% |
| Q2 2025 | 27.28% |
| Q1 2025 | -21.62% |
| Q4 2024 | 5.51% |
| Q3 2024 | 8.94% |
| Q2 2024 | 3.13% |
| Q1 2024 | 8.97% |
| Q4 2023 | 4.27% |
| Q3 2023 | -34.32% |
| Q2 2023 | 1.27% |
| Q1 2023 | 61.72% |
| Q4 2022 | -36.95% |
| Q3 2022 | -3.55% |
| Q2 2022 | 17.73% |
| Q1 2022 | 8.08% |
| Q4 2021 | -110.62% |
| Q3 2021 | -3.95% |
| Q2 2021 | -18.49% |
| Q1 2021 | -31.13% |
| Q4 2020 | 32.76% |
| Q3 2020 | -179.13% |
| Q2 2020 | 245.62% |
| Q1 2020 | -4.46% |
| Q4 2019 | -28.72% |
| Q3 2019 | 2.32% |
| Q2 2019 | -16.10% |
| Q1 2019 | -58.74% |
| Q4 2018 | -209.90% |
| Q3 2018 | 69.14% |
| Q2 2018 | 8.19% |
| Q1 2018 | -17.07% |
| Q4 2017 | -8.77% |
| Q3 2017 | -11.10% |
| Q2 2017 | -19.01% |
| Q1 2017 | 1.27% |
| Q4 2016 | -0.47% |
| Q3 2016 | -0.16% |
| Q2 2016 | -3.47% |
| Q1 2016 | -4.05% |